Recordati returns to growth, with first-half beating analysts' expectation

29 July 2021

Italian drugmaker Recordati (RECI: MI) today posted financial results for the first half of 2021, showing the company is returning to growth.

Consolidated revenue, at 770.8 million euros ($909.5 million), was up by 1.4% (+4.9% at constant exchange rate) over the same period of the previous year reflecting adverse currency exchange rate effect of around 26.8 million euros and the contribution from Eligard (leuprorelin acetate) for 36.8 million euros (acquired under licence from Tolmar International in January). Revenues were ahead of consensus forecasts of 752 million euros.

Net of these effects, growth for the first half was at 0.1%, which, however, reflects the loss of exclusivity in 2020 of Urorec (silodosin) and Livazo (pitavastatin) decrease of 19.8 million euros and the impact of the pandemic, especially on seasonal flu medications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK